More on Boston Scientific (BSX -5.7%) Q2: swings to net loss of $3.4B from a profit of $146M, due to a $3.43B goodwill impairment charge from its EMEA unit, mainly because of lower long-term growth forecasts. Guidance: FQ3 adjusted EPS $0.14-$0.17 on revenue of $1.725B-$1.825B. Consensus is for $0.11 and $1.83B. FY EPS of $0.62-$0.68 on revenue of $7.2B-$7.4B. Consensus is for $0.43 and $7.45B.